Researchers discovered that reduced LCP2 protein levels drive chemotherapy resistance in natural killer/T-cell lymphoma by triggering cellular senescence. When LCP2 expression drops, it activates the IQGAP2/LaminA/C/SUV39H1 pathway, causing DNA damage and pushing cancer cells into a senescent state that makes them resistant to adriamycin treatment. Critically, two compounds—Epitalon and Chaetocin—can target this senescence pathway to restore chemotherapy sensitivity. This finding represents a significant advance in cancer resistance biology, revealing how cellular aging mechanisms can be co-opted by tumors for survival. The senescence-chemoresistance connection has broad implications beyond this rare lymphoma, potentially explaining treatment failures across multiple cancer types. The identification of LCP2 as both a biomarker and therapeutic target opens new avenues for combination therapies. Using senolytic drugs to eliminate therapy-resistant senescent cells could revolutionize treatment of relapsed cancers, though clinical translation requires validation of safety and efficacy in human trials.